Bayer, CRISPR form gene editing JV

Bayer AG (Xetra:BAYN) and CRISPR Therapeutics AG (Basel, Switzerland) will create a joint venture to develop therapeutics for blood disorders, blindness and congenital heart disease, including systemic in vivo therapies, using CRISPR- Cas9 technology.

CRISPR Therapeutics CEO Rodger Novak told BioCentury the JV will target indications including hemophilia and Stargardt's disease. Novak expects the partners will submit one to three INDs within the next five years. ...